World Health Organization. (2022). Haematopoietic and lymphoid tissue tumours. WHO Classification of Tumours, 5th Edition.
[2]
Swerdlow SH, Campo E, Harris NL, et al. (2017). WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues. IARC Press, Lyon.
[3]
Cheson BD, Fisher RI, Barrington SF, et al. (2014). Recommendations for initial evaluation, staging, and response assessment of Hodgkin and non-Hodgkin lymphoma: the Lugano classification. J Clin Oncol. 32(27):3059-3068.
[4]
Zelenetz AD, Gordon LI, Abramson JS, et al. (2023). NCCN Guidelines Version 1.2023: B-Cell Lymphomas. National Comprehensive Cancer Network.
[5]
Hallek M, Cheson BD, Catovsky D, et al. (2018).iwcld guidelines for diagnosis, indications for treatment, response assessment and supportive management of chronic lymphocytic leukemia. Blood. 131(25):2745-2760.
[6]
Kumar SK, Callander NS, Adekola K, et al. (2023). Multiple Myeloma, Version 3.2023, NCCN Clinical Practice Guidelines in Oncology. J Natl Compr Canc Netw. 21(1):1-18.
[7]
European Society for Medical Oncology (ESMO). (2022). Guidelines for Haematological Malignancies.
[8]
Indonesian Society of Hematology and Transfusion Medicine. (2022). Panduan Praktik Klinis Penyakit Hematologi.